🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Gazyva Placebo, Gazyvaro 1,000 mg concentrate for solution for infusion.

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  2. Gefarnate

    The First People's Hospital of Lianyungang

    Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  3. Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  4. Gemcitabine Eugia 40 mg/ml solution à diluer pour perfusion, RILVEGOSTOMIG, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Hihg risk of cholangiocarcinoma intra hépatic resectable

    phase 3 small molecule active

    1 trial

  5. General anesthesia and opioids

    Elan Pharma International

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  6. Gilteritinib

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  7. Givinostat 50 mg capsules, RIVAROXABAN , ACETYLSALICYLIC ACID , Givinostat 100 mg capsules, HYDROXYCARBAMIDE, ENOXAPARIN , -, Givinostat 75 mg capsules, DABIGATRAN ETEXILATE

    Italfarmaco S.p.A.

    JAK2V617F-positive high-risk Polycythemia Vera

    phase 3 small molecule active

    1 trial

  8. Givosiran

    Alnylam Netherlands B.V.

    Acute Hepatic Porphyria

    phase 3 small molecule completed

    1 trial

  9. Glipizide

    GlaxoSmithKline

    Atherosclerosis

    phase 3 small molecule completed

    1 trial

  10. Glycerin Suppository

    United Therapeutics Europe Ltd

    Encopresis

    phase 3 small molecule completed

    1 trial

  11. Gonal-F

    The First People's Hospital of Lianyungang

    Anovulation

    phase 3 mab completed

    1 trial

  12. Grafalon 20 mg/ml concentrato per soluzione per infusione

    The George Institute

    To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.

    phase 3 small molecule active

    1 trial

  13. HEPARIN , NADROPARIN

    Disc Medicine

    All patients who receive ECMO treatment during the study period in one the participating centers from which (deferred) informed consent is obtained. Patients in whom the ECMO is only used to bridge a procedure like a high risk percutaneous coronary intervention or during surgery are excluded.

    phase 3 small molecule active

    1 trial

  14. HIPEC with neoadjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 3 other active

    1 trial

  15. HOLOXAN 2000 mg, poudre pour usage parentéral, DETICENE 100 mg, poudre et solvant pour solution pour perfusion, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Resectable, non-metastatic soft-tissue sarcoma (STS)

    phase 3 small molecule active

    1 trial

  16. HVA

    The First People's Hospital of Lianyungang

    Newly Diagnosed Acute Myeloid Leukemia With High Risk

    phase 3 small molecule active

    1 trial

  17. HYDROXYCHLOROQUINE, METHOTREXATE, Remsima 120 mg solution for injection in pre-filled pen, METHOTREXATE, IBUPROFEN, Placebo (To evaluate the efficacy and safety of CT-P13, and mainatain blindness during the study, Placebo will be administered.), PARACETAMOL, FOLIC ACID, HYDROCORTISONE

    Celltrion Healthcare Australia Pty Ltd

    Rheumatoid arthritis

    phase 3 small molecule active

    1 trial

  18. Hexaxim®

    Sanofi Pasteur

    Diphtheria

    phase 3 mab completed

    1 trial

  19. Home non-invasive ventilation

    United Therapeutics Europe Ltd

    Hypercapnic Respiratory Failure

    phase 3 other completed

    1 trial

  20. Hormonal Contraception

    United Therapeutics Europe Ltd

    Pregnancy

    phase 3 small molecule completed

    1 trial

  21. Hormone replacement therapy (estrogen/progestin)

    United Therapeutics Europe Ltd

    Anorexia Nervosa

    phase 3 small molecule completed

    1 trial

  22. Household-based water treatment with NADCC tablets

    United Therapeutics Europe Ltd

    Diarrhoea

    phase 3 other completed

    1 trial

  23. Humira 40 mg solution for injection in pre-filled syringe, ORENCIA 50 mg solution for injection in pre-filled syringe, Tyenne 162mg/0.9ml solution for injection in pre-filled syringe, Humira 20 mg solution for injection in pre-filled syringe, XELJANZ 1 mg/mL oral solution, Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 25 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, XELJANZ 5 mg film-coated tablets, ORENCIA 87.5 mg solution

    The George Institute

    Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  24. Hylenex

    HALOZYME THERAPEUTICS, INC.

    Pain

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources